Clinical effectiveness of calcitriol and calcium gluconate in treating older male patients with osteoporosis

Clinical studies on calcitriol in osteoporosis (OP) have been mostly conducted in postmenopausal women, with limited research reported in elderly male patients. In this study, we investigated the effects of combining calcitriol with calcium gluconate for treating OP in elderly men and compared it with calcium gluconate monotherapy to provide insights into the clinical treatment options for OP. A total of 86 elderly male OP patients were included in this study and randomly assigned to control or observation groups in a 1:1 ratio. The control group was given oral calcium gluconate (1.0 g, three times daily), while the observation group was given oral calcitriol capsule (0.25 µg twice daily) and oral calcium gluconate (1.0 g three times daily). The results indicated that treatment with single calcium gluconate for 6 months had minimal impact on the bone mineral density (BMD) of the lumbar spine, total hip and femoral neck, and balance function. In contrast, the combination of calcium gluconate and calcitriol significantly increased BMD and improved patients’ balance function. Both single calcium gluconate treatment and the combination of calcium gluconate and calcitriol affected various bone metabolism and turnover markers to varying degrees, including a decrease in the level of tartrate-resistant acid phosphatase-5b (TRAP-5b) and an increase in the levels of osteocalcin and calcium. Both calcium gluconate and calcitriol affect patients’ bone metabolism and turnover markers to varying degrees. Importantly, the combination of calcium gluconate and calcitriol had a significant effect on these markers compared to calcium gluconate monotherapy, and no significant difference in the incidence of adverse reactions was observed between the two groups during treatment. Calcium gluconate in combination with calcitriol in elderly male patients with OP may increase bone mineral density, improve bone metabolism, enhance bone turnover and maintain a high safety profile.

Calcium gluconate; Calcitriol; Older men; Osteoporosis; Bone density

[1] Brown JP. Long-term treatment of postmenopausal osteoporosis. Endocrinology and Metabolism. 2021; 36: 544–552.

[2] Johnston CB, Dagar M. Osteoporosis in older adults. Medical Clinics of North America. 2020; 104: 873–884.

[3] Coughlan T, Dockery F. Osteoporosis and fracture risk in older people. Clinical Medicine. 2014; 14: 187–191.

[4] Muñoz M, Robinson K, Shibli-Rahhal A. Bone health and osteoporosis prevention and treatment. Clinical Obstetrics & Gynecology. 2020; 63: 770–787.

[5] Lung BE, Mowery ML, Komatsu DEE. Calcitriol. StatPearls Publishing: Treasure Island (FL). 2024.

[6] Ringe JD. Plain vitamin D or active vitamin D in the treatment of osteoporosis: where do we stand today? Archives of Osteoporosis. 2020; 15: 182.

[7] Dechant KL, Goa KL. Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis. Drugs & Aging. 1994; 5: 300–317.

[8] Aspray TJ, Hill TR. Osteoporosis and the ageing skeleton. Subcellular Biochemistry. 2019; 12: 453–476.

[9] Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, et al. The prevalence of osteoporosis in China, a nationwide, multicenter DXA survey. Journal of Bone and Mineral Research. 2019; 34: 1789–1797.

[10] Chakraborty A, Can AS. Calcium gluconate. StatPearls Publishing: Treasure Island (FL). 2022.

[11] Li R, Wang X, Luan J, Zhang T. Effects of salmon calcitonin combined with calcium gluconate on bone metabolism in senile osteoporosis patients. Chinese Journal of Osteoporosis. 2012; 18: 3.

[12] Yong E, Logan S. Menopausal osteoporosis: screening, prevention and treatment. Singapore Medical Journal. 2021; 62: 159–166.

[13] Capozzi A, Scambia G, Lello S. Calcium, vitamin D, vitamin K2, and magnesium supplementation and skeletal health. Maturitas. 2020; 140: 55–63.

[14] Gradilone A, Ribuffo D, Silvestri I, Cigna E, Gazzaniga P, Nofroni I, et al. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance. Annals of Surgical Oncology. 2004; 11: 983–987.

[15] Yang R, Chen J, Zhang J, Qin R, Wang R, Qiu Y, et al. 1,25-Dihydroxyvitamin D protects against age-related osteoporosis by a novel VDR-Ezh2-p16 signal axis. Aging Cell. 2020; 19: e13095.

[16] Tilyard MW, Spears GFS, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. New England Journal of Medicine. 1992; 326: 357–362.

[17] Avenell A, Mak JC, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database of Systematic Reviews. 2014; 2014: CD000227.

[18] Williams C, Sapra A. Osteoporosis markers. StatPearls Publishing: Treasure Island (FL). 2023.

[19] Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. The Lancet Diabetes & Endocrinology. 2017; 5: 908–923.

[20] Szulc P. Bone turnover: biology and assessment tools. Best Practice & Research Clinical Endocrinology & Metabolism. 2018; 32: 725–738.

[21] Riancho JA. Diagnostic approach to patients with low serum alkaline phosphatase. Calcified Tissue International. 2023; 112: 289–296.

[22] Tourkova IL, Larrouture QC, Onwuka KM, Liu S, Luo J, Schlesinger PH, et al. Age-related decline in bone mineral transport and bone matrix proteins in osteoblasts from stromal stem cells. American Journal of Physiology-Cell Physiology. 2023; 325: C613–C622.

[23] Parveen B, Parveen A, Vohora D. Biomarkers of osteoporosis: an update. Endocrine, Metabolic & Immune Disorders-Drug Targets. 2019; 19: 895–912.

[24] Brown JP, Don-Wauchope A, Douville P, Albert C, Vasikaran SD. Current use of bone turnover markers in the management of osteoporosis. Clinical Biochemistry. 2022; 109–110: 1–10.

[25] Wang D, Song J, Ma H. An in vitro experimental insight into the osteoblast responses to vitamin D3 and its metabolites. Pharmacology. 2018; 101: 225–235.

[26] Gram J. Dose-response effect of short-term calcitriol treatment on bone and mineral metabolism in normal males. Bone. 1996; 18: 539–544.

[27] Ryan BA, McGregor NE, Kirby BJ, Al-Tilissi A, Poulton IJ, Sims NA, et al. Calcitriol-dependent and -independent regulation of intestinal calcium absorption, osteoblast function, and skeletal mineralization during lactation and recovery in mice. Journal of Bone and Mineral Research. 2020; 37: 2483–2497.

[28] Kassem M, Kveiborg M, Eriksen EF. Production and action of transforming growth factor-beta in human osteoblast cultures: dependence on cell differentiation and modulation by calcitriol. European Journal of Clinical Investigation. 2000; 30: 429–437.

[29] Turner AG, Hanrath MA, Morris HA, Atkins GJ, Anderson PH. The local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation. The Journal of Steroid Biochemistry and Molecular Biology. 2014; 144: 114–118.